Quote · The Prof G Pod with Scott Galloway
Why People Are Losing Faith in Healthcare
Where this was said
Lilly's Competitive Advantage: Bet Early, Move Fast, Execute Well
At 35:45 · chapter starts 31:10
Galloway frames the question bluntly: Lilly's stock is up fivefold in five years and is worth more than J&J, Pfizer, and Merck combined. What's the secret? Ricks identifies three factors. First, capital allocation: Lilly committed to GLP-1s in 2018, when the obesity drug market was considered a non-market — the bad history of fen-phen and earlier failures had scared everyone off. Lilly bet anyway because the biology was compelling. Second, speed: when Ricks became CEO, it took Lilly 11 years from invention to market — longer than the remaining patent life of the drug. They've since cut that by five years, giving them a decisive edge over rivals who haven't. Third, culture: Lilly has never had a major merger, is based in Indianapolis rather than a biotech hub, has fewer than 50,000 employees, and maintains a Midwest nice ethos where senior leaders know each other and can solve problems without committee meetings. Ricks frames the overall philosophy as going where others won't: 'By the time a medicine market is big, it's basically too late to invest.'
Lilly bet on GLP-1s in 2018 when nobody else was — obesity was considered a non-market. Combined with a 5-year cut in R&D cycle time and a singular Midwestern execution culture, those three factors compounded into a trillion-dollar market cap and fivefold stock return.
Eli Lilly's stock has risen fivefold over the past five years, making it the first healthcare company to achieve a trillion-dollar market capitalization.
Eli Lilly reduced its drug development cycle from 11 years to around 6, giving it a substantial competitive advantage in patent-protected market time.
